Sandbox/guillermo: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:




<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font><ref name="van de Beek-2010">{{Cite journal  | last1 = van de Beek | first1 = D. | last2 = Drake | first2 = JM. | last3 = Tunkel | first3 = AR. | title = Nosocomial bacterial meningitis. | journal = N Engl J Med | volume = 362 | issue = 2 | pages = 146-54 | month = Jan | year = 2010 | doi = 10.1056/NEJMra0804573 | PMID = 20071704 }}</ref><ref name="van de Beek-2012">{{Cite journal  | last1 = van de Beek | first1 = D. | last2 = Brouwer | first2 = MC. | last3 = Thwaites | first3 = GE. | last4 = Tunkel | first4 = AR. | title = Advances in treatment of bacterial meningitis. | journal = Lancet | volume = 380 |issue = 9854 | pages = 1693-702 | month = Nov | year = 2012 | doi = 10.1016/S0140-6736(12)61186-6 | PMID = 23141618 }}</ref></SMALL>
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL>


{|
{|
Line 87: Line 87:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazol]] 250 mg orally q6—8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazol]] 250 mg orally q6h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Tetracycline]] 500 mg orally q6—8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Tetracycline]] 500 mg orally q6h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ranitidine]] 150 mg orally q12h'''''<BR> OR <BR> ▸ '''''[[PPI]]standard dose'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ranitidine]] 150 mg orally q12h'''''<BR> OR <BR> ▸ '''''[[PPI]] standard dose'''''
|-
|-
|}
|}

Revision as of 20:15, 2 June 2014

Helicobacter pylori medical treatment

▸ Click on the following categories to expand treatment regimens.

First line

  ▸  Triple therapy

  ▸  Quadruple therapy

Second line

  ▸  Triple therapy

  ▸  Sequential therapy

  ▸  Hybrid therapy

Third line therapy (Rescue therapy)

  ▸  Rifabutin based

Triple therapy
PPI standard dose
PLUS
Clarithromycin 500 mg q12h.
PLUS
Amoxicillin 1,0000 mg q12h
Quadruple therapy
Bismuth subsalicylate 525 mg orally q6h
PLUS
Metronidazol 250 mg orally q6h
PLUS
Tetracycline 500 mg orally q6h
PLUS
Ranitidine 150 mg orally q12h
OR
PPI standard dose
Triple therapy
PPI standard dose
PLUS
Clarithromycin 500 mg q12h
PLUS
Metronidazole 500 mg q12h
Sequential therapy
First 5 days
PPI standard dose
PLUS
Amoxicillin 1,000 mg q12h
Next 5 days
PPI standard dose
Clarithromycin 500 mg q12h
PLUS
Tinidazol 500 mg q12h
Sequential therapy
First 7 days
PPI standard dose
PLUS
Amoxicillin 1,000 mg q12h
Next 7 days
PPI standard dose
PLUS
Amoxicillin 1,000 mg q12h
PLUS
Clarithromycin 500 mg q12h
PLUS
Metronidazol 500 mg q12h
Third line treatment
Rifabutin 150 mg q2h
PLUS
Amoxicillin 1,000 mg IV q12h
PLUS
Ciprofloxacin 500 mg/kg IV q12h

References